The aim of this study is to evaluate safety, and tolerability of insulin LY3209590 following a single dose given to children with type 2 diabetes mellitus (T2DM). This will be the first study to evaluate LY3209590 in pediatric patients with T2DM.

Screening:

All participants will be screened up to 28 days prior to dosing.

Treatment and Assessment Period:

On Day 1, participants will receive a single 100-Unit subcutaneous dose of LY3209590 at the clinical research unit.

Follow up research visits will be performed on Days 3, 5, 7, 15, 29, 43, and 65. Blood sampling and safety assessments will be performed at each in clinic visit. Before each study visit, subjects will need to fast for at least 8 hours.

A follow-up telephone call will be performed on approximately Day 72. The total time for participation is the study is about 100 days.

The goals of this research study are to find out how having COVID-19 recently affects blood sugar, inflammation, and insulin in people with type 1 and type 2 diabetes. We also want to see if COVID-19 changes blood vessel health or makes blood clot more easily. We will also look at how things like genes, lifestyle, and environment might affect these issues.

We are trying to learn more about the ways in which adolescents (12-17 years) are involved in decision making related to their chronic condition. We are hoping to partner with families who are planning to attend or recently attended a visit in the Comprehensive Sickle Cell Center, Diabetes Center for Children, Center for Inflammatory Bowel Disease, or the Division of Rheumatology at CHOP.

If you and your child are able to help us, you will each be asked to complete a questionnaire about your experiences during a recent clinic visit. Additionally, a random selection of parents and teens will be asked to complete an interview with our team. All participants will be compensated for their participation in this study.

It is essential that we speak to families before or immediately following their scheduled visit at CHOP.